AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35462610 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 201
Study 33012187 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan
Number of subjects: 0
Study 33012187 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐α
Number of subjects: 0
Study 33012187 — intervention group
Group type: EXPERIMENTAL
Intervention: Imetelstat
Number of subjects: 0
Study 33012187 — intervention group
Group type: EXPERIMENTAL
Intervention: New experimental drugs and drug combinations
Number of subjects: 0
Study 35385366 — intervention group
Group type: EXPERIMENTAL
Intervention: Online learning only
Number of subjects: 83
Study 35385366 — intervention group
Group type: EXPERIMENTAL
Intervention: Online learning with the use of specimen equine bones
Number of subjects: 83
Study 35385366 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning on conventional radiographs with specimen equine bones
Number of subjects: 83
Study 35385366 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 83
Study 33977736 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib combined with OxyContin and Pregabalin (experimental group)
Number of subjects: 51
Study 33977736 — intervention group
Group type: COMPARATOR
Intervention: OxyContin combined with Pregabalin (control group)
Number of subjects: 51
Study 33977736 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride sustained-release capsules (for urinary dysfunction in both groups)
Number of subjects: 51
Study 32708894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (2 × 00 mg)
Number of subjects: 8
Study 32708894 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study 33684963 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvisational theatre exercises (45-minute communication-focused intervention)
Number of subjects: 188
Study 33684963 — intervention group
Group type: COMPARATOR
Intervention: Control arm without intervention
Number of subjects: 188
Study 33340917 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week online Cognitive Behavioral Therapy for Insomnia (CBT-I) program
Number of subjects: 30
Study 33340917 — intervention group
Group type: COMPARATOR
Intervention: Six weeks of online psychoeducational modules on insomnia and grief (Control)
Number of subjects: 30
Study 34963177 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (Group A)
Number of subjects: 150
Study 34963177 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (Group B)
Number of subjects: 150
Study 34963177 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 33066973 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily for 6 months
Number of subjects: 1686
Study 33066973 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg twice daily for 6 months
Number of subjects: 1686
Study 33066973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1686
Study 32691110 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct methods group using a straight line from the anal verge to the tumor
Number of subjects: 50
Study 32691110 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mass method (recommended)
Number of subjects: 50
Study 32691110 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower end of the external anal sphincter as a landmark
Number of subjects: 50
Study 32488233 — intervention group
Group type: EXPERIMENTAL
Intervention: HUMMUS
Number of subjects: 39
Study 32488233 — intervention group
Group type: COMPARATOR
Intervention: BARS
Number of subjects: 39
Study 32488233 — intervention group
Group type: COMPARATOR
Intervention: NO SNACK
Number of subjects: 39
Study 35026855 — intervention group
Group type: EXPERIMENTAL
Intervention: Telementoring
Number of subjects: 23
Study 35026855 — intervention group
Group type: COMPARATOR
Intervention: In-person training
Number of subjects: 23
Study 34366847 — intervention group
Group type: EXPERIMENTAL
Intervention: TQ-F3083 (2 to 160 mg)
Number of subjects: 60
Study 34366847 — intervention group
Group type: EXPERIMENTAL
Intervention: TQ-F3083 (multiple doses for 7 days)
Number of subjects: 60
Study 34366847 — intervention group
Group type: EXPERIMENTAL
Intervention: TQ-F3083 (after high-fat and high-calorie breakfast)
Number of subjects: 60
Study 34366847 — intervention group
Group type: EXPERIMENTAL
Intervention: TQ-F3083
Number of subjects: 60
Study 34366847 — intervention group
Group type: EXPERIMENTAL
Intervention: TQ-F3083 (20–160 mg cohorts)
Number of subjects: 60
Study 32596199 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement microbreaks during work hours
Number of subjects: 43
Study 32596199 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 43
Study 35227219 — intervention group
Group type: EXPERIMENTAL
Intervention: Underbody forced-air warming (FAW) blankets
Number of subjects: 100
Study 35227219 — intervention group
Group type: COMPARATOR
Intervention: Overbody forced-air warming (FAW) blankets
Number of subjects: 100
Study 33206193 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐cigarette group (125 participants)
Number of subjects: 186
Study 33206193 — intervention group
Group type: COMPARATOR
Intervention: control group (61 participants)
Number of subjects: 186
Study 34494204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid challenge over 10 minutes (FC10)
Number of subjects: 49
Study 34494204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid challenge over 20 minutes (FC20)
Number of subjects: 49
Study 33848758 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 896
Study 33848758 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination NRT
Number of subjects: 896
Study 33848758 — intervention group
Group type: COMPARATOR
Intervention: NRT
Number of subjects: 896
Study 36329525 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth exercise intervention (90 min of exercise per week for 8 weeks)
Number of subjects: 60
Study 36329525 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth exercise intervention
Number of subjects: 60
Study 36329525 — intervention group
Group type: COMPARATOR
Intervention: Delayed control group
Number of subjects: 60
Study 34130753 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 105
Study 34130753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 32616033 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived availability of social support (appraisal support)
Number of subjects: 0
Study 32616033 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived availability of social support (belonging support)
Number of subjects: 0
Study 32616033 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived availability of social support (tangible support)
Number of subjects: 0
Study 32616033 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived availability of social support (overall)
Number of subjects: 0
Study 35195745 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional Ultrasound Skills Evaluation (IUSE) tool
Number of subjects: 18
Study 35195745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pass/fail score of the IUSE tool
Number of subjects: 18
Study 32826319 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE at 1.17 ± 0.09 GBq/cycle
Number of subjects: 32
Study 32826319 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE at 1.89 ± 0.53 GBq/cycle
Number of subjects: 32
Study 32826319 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE at 3.97 ± 0.84 GBq/cycle
Number of subjects: 32
Study 35614467 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate
Number of subjects: 0
Study 35614467 — intervention group
Group type: EXPERIMENTAL
Intervention: One moderate exacerbation
Number of subjects: 0
Study 35614467 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥2 moderate exacerbations
Number of subjects: 0
Study 34312262 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of social determinants of health (SDoH) insecurities
Number of subjects: 2763
Study 34312262 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional capacity
Number of subjects: 2763
Study 34312262 — intervention group
Group type: EXPERIMENTAL
Intervention: Each insecurity (food, housing, financial)
Number of subjects: 2763
Study 32838838 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 179918
Study 32838838 — intervention group
Group type: COMPARATOR
Intervention: Anakinra
Number of subjects: 179918
Study 35120178 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfortable walking speed (cws)
Number of subjects: 41
Study 35120178 — intervention group
Group type: EXPERIMENTAL
Intervention: Long stepping on the paretic side (p-long)
Number of subjects: 41
Study 35120178 — intervention group
Group type: EXPERIMENTAL
Intervention: Long stepping on the non-paretic side (np-long)
Number of subjects: 41
Study 34583969 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation
Number of subjects: 415
Study 34583969 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 415
Study 35860416 — intervention group
Group type: EXPERIMENTAL
Intervention: Transauricular vagus nerve stimulation (taVNS)
Number of subjects: 78
Study 35860416 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (SS)
Number of subjects: 78
Study 34628720 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose napabucasin (80-1200 mg)
Number of subjects: 70
Study 34628720 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose napabucasin (240-1200 mg)
Number of subjects: 70
Study 34628720 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose napabucasin (240-720 mg)
Number of subjects: 70
Study 34628720 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose napabucasin
Number of subjects: 70
Study 32223688 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct rigid laryngoscope during suspension laryngoscopy (SL) procedures
Number of subjects: 64
Study 32223688 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 64
Study 36171512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 36171512 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 34363478 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise (60% to 80% of heart rate reserve, 3 times per week for 12 months)
Number of subjects: 250
Study 34363478 — intervention group
Group type: COMPARATOR
Intervention: Usual and customary care
Number of subjects: 250
Study 32453996 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 10
Study 32453996 — intervention group
Group type: COMPARATOR
Intervention: Control group (intensive bi-manual treatment)
Number of subjects: 10
Study 33439831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 216
Study 33439831 — intervention group
Group type: COMPARATOR
Intervention: Atosiban (competitive antagonist of oxytocin and vasopressin receptors)
Number of subjects: 216
Study 33439831 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin (not administered)
Number of subjects: 216
Study 32817130 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/nab-paclitaxel plus pamrevlumab (Arm A, n=24)
Number of subjects: 37
Study 32817130 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine/nab-paclitaxel minus pamrevlumab (Arm B, n=13)
Number of subjects: 37
Study 36421696 — intervention group
Group type: EXPERIMENTAL
Intervention: rhFGF-2 plus DBBM
Number of subjects: 32
Study 36421696 — intervention group
Group type: COMPARATOR
Intervention: rhFGF-2
Number of subjects: 32
Study 34334790 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (61 g fat)
Number of subjects: 13
Study 34334790 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal (10 g fat)
Number of subjects: 13
Study 616117222 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional corneal collagen cross-linking (CXL)
Number of subjects: 45
Study 616117222 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated corneal collagen cross-linking (CXL)
Number of subjects: 45
Study 616117222 — intervention group
Group type: EXPERIMENTAL
Intervention: Transepithelial by iontophoresis CXL
Number of subjects: 45
Study 35653395 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisolone (AAP)
Number of subjects: 1917
Study 35653395 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 1917
Study 32445277 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhalation delivery system with fluticasone (EDS-FLU)
Number of subjects: 643
Study 32445277 — intervention group
Group type: COMPARATOR
Intervention: Placebo (EDS-PBO)
Number of subjects: 643
Study 35427994 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day educational program
Number of subjects: 184
Study 35427994 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 184
Study 33012276 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Feet 4 Life intervention (nurse-led, one hour/week for four consecutive weeks)
Number of subjects: 29
Study 616855345 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Anaesthesia
Number of subjects: 0
Study 35378798 — intervention group
Group type: EXPERIMENTAL
Intervention: PPB in primiparas
Number of subjects: 657
Study 35378798 — intervention group
Group type: EXPERIMENTAL
Intervention: PPB in multiparas
Number of subjects: 657
Study 32601909 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications graded by Clavien–Dindo classification (≥ C-D grade II)
Number of subjects: 1191
Study 32601909 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications graded by Clavien–Dindo classification (≥ C-D grade III)
Number of subjects: 1191
Study 32601909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal infectious complications (≥ grade II)
Number of subjects: 1191
Study 32601909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal infectious complications (≥ grade III)
Number of subjects: 1191
Study 32601909 — intervention group
Group type: EXPERIMENTAL
Intervention: Any ≥ C-D grade III complication
Number of subjects: 1191
Study 32601909 — intervention group
Group type: EXPERIMENTAL
Intervention: All four definitions of complications
Number of subjects: 1191
Study 35503499 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT‐AFL‐2W
Number of subjects: 90
Study 35503499 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT‐AFL‐4W
Number of subjects: 90
Study 33082217 — intervention group
Group type: COMPARATOR
Intervention: Mechanical Insufflation-Exsufflation (MI-E)
Number of subjects: 19
Study 33082217 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Insufflation-Exsufflation with oscillations (MI-E + oscillations)
Number of subjects: 19
Study 35565669 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional support to reach energy, protein, and micronutrient goals
Number of subjects: 645
Study 35565669 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital food
Number of subjects: 645
Study 34246265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=74)
Number of subjects: 146
Study 34246265 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=72)
Number of subjects: 146
Study 35930728 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week MTX hold
Number of subjects: 178
Study 35930728 — intervention group
Group type: COMPARATOR
Intervention: 2 week MTX hold
Number of subjects: 178
Study 33190135 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.4 mg daily for 10 days)
Number of subjects: 73
Study 33190135 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 73
Study 33190135 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (meta-analysis)
Number of subjects: 73
Study 36106651 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physical activity intervention (standard postoperative physical therapy plus goal setting, problem-solving, and motivational interviewing techniques)
Number of subjects: 45
Study 36106651 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative physical therapy only (control group)
Number of subjects: 45
Study 32448693 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine
Number of subjects: 50
Study 32448693 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 50
Study 34288776 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture group
Number of subjects: 170
Study 34288776 — intervention group
Group type: COMPARATOR
Intervention: Sutureless hydroclosure group
Number of subjects: 170
Study 35339234 — intervention group
Group type: EXPERIMENTAL
Intervention: Astegolimab (490 mg subcutaneous every 4 weeks for 44 weeks)
Number of subjects: 0
Study 35339234 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous every 4 weeks for 44 weeks)
Number of subjects: 0
Study 35339234 — intervention group
Group type: EXPERIMENTAL
Intervention: Astegolimab
Number of subjects: 0
Study 33452047 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoallergenic medical wig
Number of subjects: 59
Study 33452047 — intervention group
Group type: COMPARATOR
Intervention: Traditional medical wig
Number of subjects: 59
Study 32987360 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation plus Sonification (AOS) protocol
Number of subjects: 0
Study 32987360 — intervention group
Group type: COMPARATOR
Intervention: External sensory cues
Number of subjects: 0
Study 35660357 — intervention group
Group type: EXPERIMENTAL
Intervention: double Maddox test
Number of subjects: 25
Study 35660357 — intervention group
Group type: COMPARATOR
Intervention: synoptophore
Number of subjects: 25
Study 35660357 — intervention group
Group type: EXPERIMENTAL
Intervention: Gracis torsionometer
Number of subjects: 25
Study 35660357 — intervention group
Group type: EXPERIMENTAL
Intervention: Harms screen
Number of subjects: 25
Study 35660357 — intervention group
Group type: EXPERIMENTAL
Intervention: Awaya test
Number of subjects: 25
Study 35660357 — intervention group
Group type: COMPARATOR
Intervention: synoptophore vs Gracis torsionometer
Number of subjects: 25
Study 35660357 — intervention group
Group type: COMPARATOR
Intervention: synoptophore vs Awaya test
Number of subjects: 25
Study 32512380 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ropivacaine (0.2%) at 10 mL/h for 48 h
Number of subjects: 150
Study 32512380 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ropivacaine (0.2%)
Number of subjects: 150
Study 32512380 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (0.9%)
Number of subjects: 150
Study 33991350 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg every 12 hours for 14 days)
Number of subjects: 16
Study 33991350 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline (400 mg once daily for 2 weeks, followed by 200 mg twice a week for 46 weeks) with clarithromycin
Number of subjects: 16
Study 33991350 — intervention group
Group type: COMPARATOR
Intervention: Bedaquiline monotherapy (400 mg once daily for 2 weeks, followed by 200 mg 3 times a week for 46 weeks)
Number of subjects: 16
Study 35484186 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 26
Study 35484186 — intervention group
Group type: COMPARATOR
Intervention: Nasal cannula (NC)
Number of subjects: 26
Study 34759229 — intervention group
Group type: EXPERIMENTAL
Intervention: Parylene-coated occluder
Number of subjects: 108
Study 34759229 — intervention group
Group type: COMPARATOR
Intervention: Traditional nitinol-containing device
Number of subjects: 108
Study 36409190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower Seed Oil (SSO)
Number of subjects: 90
Study 36409190 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid Vaseline (LV)
Number of subjects: 90
Study 36409190 — intervention group
Group type: COMPARATOR
Intervention: Control (no moisturizer)
Number of subjects: 90
Study 32747650 — intervention group
Group type: EXPERIMENTAL
Intervention: vBMD of femoral head on non-fracture side
Number of subjects: 367
Study 32747650 — intervention group
Group type: COMPARATOR
Intervention: vBMD of femoral head on fracture side
Number of subjects: 367
Study 34169613 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA-002 (low-dose 3 × 10^6 cells)
Number of subjects: 26
Study 34169613 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA-002 (high-dose 30 × 10^6 cells)
Number of subjects: 26
Study 34169613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 32259301 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral stimulation intervention
Number of subjects: 211
Study 32259301 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 211
Study 34418665 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus cetuximab
Number of subjects: 243
Study 34418665 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 243
Study 32383285 — intervention group
Group type: EXPERIMENTAL
Intervention: Starter containing 160 g/kg CP (65 g/kg RUP, based on DM)
Number of subjects: 42
Study 32383285 — intervention group
Group type: EXPERIMENTAL
Intervention: Starter containing 180 g/kg CP (65 g/kg RUP, based on DM)
Number of subjects: 42
Study 32383285 — intervention group
Group type: EXPERIMENTAL
Intervention: Starter containing 200 g/kg CP (62 g/kg RUP, based on DM)
Number of subjects: 42
Study 35640500 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-Led Online Modules
Number of subjects: 80
Study 35640500 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Modules
Number of subjects: 80
Study 35640500 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 80
Study 33124686 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH)
Number of subjects: 11
Study 32978541 — intervention group
Group type: EXPERIMENTAL
Intervention: C+P
Number of subjects: 1058
Study 32978541 — intervention group
Group type: EXPERIMENTAL
Intervention: B+P
Number of subjects: 1058
Study 32978541 — intervention group
Group type: EXPERIMENTAL
Intervention: PA
Number of subjects: 1058